Óscar Muñoz Aznar
Técnico
Research group
Professional network profiles
Last Publications
- Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma Biorxiv . : .
- Kobialka P, Sabata H, Vilalta O, Gouveia L, Angulo-Urarte A, Muixí L, Zanoncello J, Muñoz-Aznar O, Gene-Olaciregui N, Fanlo L, Esteve-Codina A, Lavarino C, Javierre BM, Celis-Passini V, Rovira-Zurriaga C, López-Fernández S, Baselga E, Mora J, Castillo SD and Graupera M The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib EMBO Molecular Medicine . 14(7): .
- Cuadrado-Vilanova M, Liu J, Paco-Mercader S, Aschero MR, Burgeño-Sandoval V, Sirab N, Pascual-Pastó G, Correa G, Balaguer-Lluna L, Castillo H, Pérez-Jaume S, Muñoz-Aznar O, Roldan-Molina M, Suñol M, Schaiquevich P, Aerts I, Doz F, Cassoux N, Lubieniecki F, Benitez-Ribas D, Lavarino C, Mora J, Chantada G, Català-Mora J, Radvanyi F and Carcaboso AM Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients JOURNAL OF PATHOLOGY . 257(3): 327-339.
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- El epigenoma malvado de los tumores rabdoides - definir para tratar.
- Leader
- Alexandra Avgustinova
- Funding entities:
- Ministerio de Economía Y Competitividad (MINECO)
- Code
- PID2020-118241RA-I00
- Starting - finishing date:
- 2021 - 2023
- Project name:
- Medicina personalizada
- Leader
- Carmen De Torres Gómez-Pallete, Cinzia Emilia Lavarino
- Funding entities:
- Clientes Diversos, Asociación Nacional Voz para Oncología Infantil
- Code
- PFNR0080
- Starting - finishing date:
- 2016 - 3000
News
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.